SecSonar.com

MannKind Corporation (MNKD)

MannKind Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

MannKind Corporation (MNKD) is a Biotechnology company based in US with a market capitalization of $1.2B. Revenue grew 22.2% year-over-year and the company generated $13.7M in free cash flow. This page tracks MNKD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 403 employees · IPO Jul 28, 2004

Valuation

Valuation & price

$3.09 · as of May 17, 2026 · -50.2% vs 52w high

165.5

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.21$4.25$2.28Jul 25Dec 25Jun 26Jul 7, 25$3.54Jul 9, 25$3.82Jul 11, 25$3.77Jul 15, 25$3.85Jul 17, 25$3.90Jul 21, 25$3.82Jul 23, 25$4.10Jul 25, 25$4.06Jul 29, 25$3.82Jul 31, 25$3.78Aug 4, 25$3.92Aug 6, 25$3.47Aug 8, 25$3.52Aug 12, 25$3.66Aug 14, 25$3.70Aug 18, 25$3.81Aug 20, 25$3.97Aug 22, 25$4.11Aug 27, 25$4.52Aug 29, 25$4.59Sep 3, 25$5.51Sep 5, 25$5.54Sep 9, 25$5.51Sep 11, 25$5.42Sep 15, 25$5.38Sep 17, 25$5.39Sep 19, 25$5.43Sep 23, 25$5.35Sep 25, 25$5.33Sep 29, 25$5.39Oct 1, 25$5.38Oct 3, 25$5.76Oct 7, 25$5.65Oct 9, 25$5.14Oct 13, 25$5.10Oct 16, 25$5.35Oct 20, 25$5.49Oct 22, 25$5.53Oct 24, 25$5.31Oct 28, 25$5.30Oct 30, 25$5.55Nov 3, 25$5.48Nov 5, 25$6.06Nov 7, 25$5.63Nov 11, 25$5.25Nov 13, 25$5.07Nov 17, 25$4.98Nov 19, 25$5.00Nov 21, 25$5.03Nov 25, 25$5.36Nov 28, 25$5.35Dec 2, 25$5.59Dec 5, 25$5.68Dec 9, 25$5.77Dec 11, 25$5.81Dec 15, 25$5.94Dec 17, 25$5.97Dec 19, 25$5.84Dec 23, 25$5.93Dec 26, 25$5.79Dec 30, 25$5.66Jan 2, 26$5.60Jan 6, 26$5.62Jan 8, 26$6.01Jan 12, 26$5.77Jan 14, 26$5.61Jan 16, 26$5.21Jan 21, 26$5.71Jan 23, 26$5.46Jan 28, 26$5.64Jan 30, 26$5.78Feb 3, 26$6.21Feb 5, 26$5.51Feb 9, 26$5.91Feb 11, 26$5.74Feb 13, 26$5.66Feb 18, 26$5.44Feb 20, 26$5.54Feb 24, 26$5.54Feb 26, 26$3.24Mar 2, 26$3.04Mar 4, 26$2.95Mar 6, 26$2.61Mar 10, 26$2.61Mar 12, 26$2.82Mar 16, 26$2.77Mar 19, 26$2.52Mar 23, 26$2.44Mar 25, 26$2.28Mar 27, 26$2.28Mar 31, 26$2.45Apr 2, 26$2.50Apr 7, 26$2.57Apr 9, 26$2.56Apr 13, 26$2.64Apr 15, 26$2.77Apr 17, 26$2.84Apr 21, 26$2.70Apr 23, 26$2.71Apr 27, 26$2.63Apr 29, 26$2.75May 1, 26$2.84May 5, 26$2.86May 8, 26$3.52May 12, 26$3.28May 14, 26$3.22May 18, 26$2.99May 20, 26$3.25May 22, 26$3.38May 27, 26$3.55May 29, 26$3.77Jun 2, 26$3.43Jun 4, 26$3.52Jun 8, 26$3.39Jun 10, 26$3.63Jun 12, 26$3.66Jun 16, 26$3.87Jun 18, 26$3.94Jun 23, 26$3.93Jun 29, 26$4.24
$2.2852-week range$6.21
Loading valuation history…

Fundamentals

Key fundamentals

$1.2B

Market cap

22.2%

Revenue growth (YoY)

82.5%

Gross margin

$13.7M

Free cash flow (USD)

$302M

Net debt

11.4%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$174.8MFY 2017$11.7MFY 2018$27.9MFY 2019$63.0MFY 2020$65.1MFY 2021$75.4MFY 2022$99.8MFY 2023$199.0MFY 2024$285.5MFY 2025$349.0M
$174.8M$349M

Free cash flow by year

2016 → 2025

FY 2016$-79.2MFY 2017$-64.8MFY 2018$-38.1MFY 2019$-91.0MFY 2020$-32.9MFY 2021$-73.2MFY 2022$-88.3MFY 2023$-8.3MFY 2024$32.8MFY 2025$13.7M
-$79.2M$13.7M

Gross margin by year

2021 → 2025

FY 202148.5%FY 202242.4%FY 202368.5%FY 202473.2%FY 202582.5%
48.5%82.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventFDA ApprovalJun 2, 2026Filing
  • 8-K eventRegulatory UpdateMay 28, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing

Questions

Frequently asked questions

What is MannKind Corporation's market cap?

MannKind Corporation (MNKD) has a market capitalization of $1.2B.

What is MNKD's P/E ratio?

MNKD trades at a price-to-earnings ratio of 165.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying MNKD stock?

SEC Form 4 filings show no open-market insider buys at MannKind Corporation in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

AMLX

Amylyx Pharmaceuticals, Inc.

$1.2B

EYPT

EyePoint Pharmaceuticals, Inc.

$1.2B

ABSI

Absci Corporation

$1.1B

OPK

OPKO Health, Inc.

$1.1B

NKTR

Nektar Therapeutics

$1.3B

GLUE

Monte Rosa Therapeutics, Inc.

$1.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.